XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)
3 Months Ended 6 Months Ended
Sep. 28, 2016
USD ($)
Agreement
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jul. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Proceeds from the issuance of common stock         $ 250,479,000    
Revenues   $ 32,811,000 $ 23,529,000 $ 54,113,000 $ 52,983,000    
Type of Revenue [Extensible List]   arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantAndProductSalesMember arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantAndProductSalesMember    
Contract liabilities   $ 144,879,000   $ 144,879,000   $ 19,291,000  
Collaboration and License agreements | Amgen Incorporated              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Agreement date Sep. 28, 2016            
Number of agreements | Agreement 2            
Cash received as due under collaboration agreement $ 35,000,000.0            
Olpasiran Agreement | Amgen Incorporated              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payments 30,000,000.0            
Olpasiran Agreement | Amgen Incorporated | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Additional remaining development regulatory and sales milestones payments   400,000,000.0   400,000,000.0      
License Collaboration and Stock Purchase Agreement | Amgen Incorporated              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Proceeds from the issuance of common stock $ 21,500,000            
Olpasiran and ARO-AMG1 Agreement | Amgen Incorporated              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payments             $ 20,000,000.0
Revenues   $ 0 $ 0 $ 0 $ 0    
Type of Revenue [Extensible List]   us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember    
Contract assets   $ 0   $ 0      
Contract liabilities   $ 0   $ 0